Stock DNA
Pharmaceuticals & Biotechnology
CNY 18,194 Million (Large Cap)
NA (Loss Making)
NA
2.37%
0.20
-1.32%
1.72
Total Returns (Price + Dividend) 
Shandong Buchang Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
Shandong Buchang Pharmaceuticals Reports Strong Quarterly Profits Amidst Market Challenges
Shandong Buchang Pharmaceuticals Co., Ltd., a prominent player in the pharmaceuticals and biotechnology sector, has recently released its financial results for the quarter ending March 2025. Despite facing a challenging market environment, the company has demonstrated resilience with notable performance metrics.
In the latest quarter, Shandong Buchang Pharmaceuticals achieved an operating profit of CNY 377.47 MM, marking a significant milestone for the company. This figure represents the highest operating profit recorded in recent times, showcasing the company's ability to maintain profitability even in adverse conditions.
Additionally, the pre-tax profit reached CNY 373.97 MM, further underscoring the company's robust financial health. The net profit for the quarter also hit a record high of CNY 305.66 MM, reflecting effective cost management and operati...
Read full news article Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is -2.58% vs 3.38% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is -33.10% vs 3.59% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -16.72% vs -11.31% in Dec 2023
YoY Growth in year ended Dec 2024 is -562.41% vs 108.84% in Dec 2023






